Multiple Myeloma
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Experts Weigh in on Multiple Myeloma
Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.
"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD
Considerations for Real-World MM Treatment: Ajai Chari, MD
Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM
Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies
Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75)
Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Streamlining Transitions Between Academic and Community Centers
Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
Proactive CRS Management: The Role of Tocilizumab and Beyond
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
Closing Gaps in CLL Care: Managed Care Insights and Strategies
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
More News
Transforming Multiple Myeloma Care With Education and Advanced Therapies
